±àÕß°´£º£º±¾Æª±¨µÀΪ¡°ngµç×ÓÓÎÏ·¿ÆÑÐЧ¹ûϵÁб¨µÀ¡±µÄµÚÈýƪ£¬£¬½éÉÜngµç×ÓÓÎÏ·Ö×Áö·ÀÖÎÖÐÐÄÂí¿¥½ÌÊÚÑо¿ÍŶÓÒÔ±ÇÑÊ°©ÎªÖ÷ÒªÑо¿¹¤¾ßÈ¡µÃµÄÍ»ÆÆÐÔЧ¹û¡£¡£¡
£¡£

Âí¿¥½ÌÊÚÂÊÁìµÄ±ÇÑÊ°©Ñо¿ÍŶÓ£¬£¬ÔÚ¡°Ê®¶þÎ塱¹ú¼Ò¿Æ¼¼Ö§³ÖÍýÏë¡¢¡¢¡¢¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÖصãÏîÄ¿µÈ×ÊÖúÏ£¬£¬ÒÔ±ÇÑÊ°©ÎªÖ÷ÒªÑо¿¹¤¾ß£¬£¬È¡µÃÍ»ÆÆÐÔЧ¹û£¬£¬Ìá¸ßÁË»¼ÕßµÄÉúÑÄÂÊ£¬£¬¸ÄÉÆÁËÉúÑÄÆ·ÖÊ¡£¡£¡
£¡£½ü15ÄêÈ«ÇòͨÓõÄÃÀ¹ú·ÖÆÚ×öÁË6ÏîÐÞ¶©£¬£¬ÆäÖÐ4Ïî½ÓÄÉÁËËûÃǵÄЧ¹û¡£¡£¡
£¡£½ü20ÄêÌìÏÂȨÍþµÄÃÀ¹úÖÎÁÆÖ¸ÄϽö×öÁË2ÏîÐÞ¶©£¬£¬ÆäÖÐ1Ïî»ùÓÚËûÃǵÄÑо¿¡£¡£¡
£¡£Ñо¿Ð§¹û±»ÆÀΪ2012Äê¶È¡°º£ÄÚҽѧʮ´óÐÂÎÅÊÂÎñ¡±¼°¡°Öйú¸ßµÈѧУʮ´ó¿Æ¼¼Ï£Íû¡±¡£¡£¡
£¡£

Âí¿¥½ÌÊÚÒÔΨһͨѶ×÷Õß½ÒÏþSCIÂÛÖø91ƪ£¬£¬°üÀ¨¹ú¼ÊÅÅÃûµÚÒ»µÄÖ×ÁöѧÔÓÖ¾Lancet Oncol£¨IF 33.9£©3ƪ£¬£¬J ClinOncol£¨IF 24.0£©¡¢¡¢¡¢JAMA Oncol£¨IF 16.6£©ºÍAnn Oncol£¨IF 11.9£©¸÷1ƪ£»ÒÔ×îºóͨѶ×÷Õß½ÒÏþSCIÂÛÖø11ƪ£¬£¬°üÀ¨Nat Commun£¨IF 12.1£©1ƪ¡£¡£¡
£¡£ÏÖÈιúÎñԺѧλίԱ»áÌØÖÖҽѧÆÀÒé×鸱ÕÙ¼¯ÈË£¬£¬»ñÌìÏÂÓÅÒì¿Æ¼¼ÊÂÇéÕßµÈÉùÓþ³Æºô¡£¡£¡
£¡£Ïòµ¼ÍŶӻñµÃ¹ú¼Ò¿Æ¼¼Ç°½ø¶þµÈ½±2Ï2015¡¢¡¢¡¢2009£©¡¢¡¢¡¢ÌìÏÂÁ¢ÒìÕùÏȽ±×´£¨2017£©ºÍÊ¡²¿¼¶¿Æ¼¼Ò»µÈ½±5Ï£¬²¢ÀÖ³ÉÈëÑ¡½ÌÓý²¿ºÍ¿Æ¼¼²¿Á¢ÒìÍŶÓ¡£¡£¡
£¡£

Âí¿¥½ÌÊÚÍŶӺÏÓ°

¡°±ÇÑÊ°©ÕïÁÆÒªº¦Õ½ÂÔÑо¿ÓëÓ¦Óá±»ñµÃ2015Äê¹ú¼Ò¿Æ¼¼Ç°½ø¶þµÈ½±£¨µÚÒ»Íê³ÉÈË£©

¡°»ùÓÚÏÖ´úÓ°ÏñÊÖÒյıÇÑÊ°©×ÛºÏÖÎÁÆÑо¿¼°Ó¦Óá±»ñµÃ2009Äê¡°¹ú¼Ò¿Æ¼¼Ç°½ø¶þµÈ½±¡±£¨µÚÒ»Íê³ÉÈË£©

ÍŶӴø¶¯ÈËÂí¿¥½ÌÊÚ2017Äê¡°ÌìÏÂÁ¢ÒìÕùÏȽ±×´¡±

¿ËÈÕ£¬£¬¼ÇÕ߲ɷÃÁËÖ×Áö·ÀÖÎÖÐÐÄÂí¿¥½ÌÊÚÍŶÓ£¬£¬²¢Çë¸ÃÍŶӾͱÇÑÊ°©TPFÓÕµ¼»¯ÁÆÁÙ´²ÊÔÑé×÷Ïà¹Ø½éÉÜ¡£¡£¡
£¡£

¼ÇÕߣ¨ÒÔϼò³Æ¡°¼Ç¡±£©:¡°±ÇÑÊ°©TPFÓÕµ¼»¯ÁÆÁÙ´²ÊÔÑ顱µÄ˼Ð÷ÊÇÔõÑùÌá³öµÄ£¿
£¿

Âí¿¥½ÌÊÚÑо¿ÍŶӣ¨ÒÔϼò³Æ¡°Âí¡±£©£º£º±ÇÑÊ°©£¨nasopharyngeal carcinoma, NPC£©ÊÇÎÒ¹ú»ªÄϵØÇø³£¼ûµÄ¶ñÐÔÖ×ÁöÖ®Ò»¡£¡£¡
£¡£Í¬ÆÚ·Å»¯ÁÆ£¨·ÅÉäÖÎÁÆͬʱ¾ÙÐеĻ¯ÁÆ£©ÁªºÏ¸¨Öú»¯ÁÆ£¨·ÅÉäÖÎÁÆ¿¢Êºó¾ÙÐеĻ¯ÁÆ£©Êǹú¼ÊÉÏÍƼöÖÎÁƾֲ¿ÇøÓòÍíÆÚ±ÇÑÊ°©µÄ±ê×¼ÖÎÁÆ¡£¡£¡
£¡£ÎÒÃǼÈÍùµÄÑо¿·¢Ã÷£¬£¬½ÓÊܸ¨Öú»¯ÁƵĻ¼Õß½üÒ»°ë»á±¬·¢ÑÏÖØÍÂÄæµÈ¶¾¸±×÷Ó㬣¬ÔâÊÜÐí¶àÍ´¿à£¬£¬ÖÎÁÆЧ¹ûÈ´²¢²»²ÇÏ룬£¬ÈÔÓÐ20-30%µÄ²¡ÈËÔÚÖÎÁƺó·ºÆðÔ¶´¦×ªÒÆ¡£¡£¡
£¡£Òò´Ë£¬£¬ÒªïÔÌ­²¡È˵ÄÍ´¿à£¬£¬¸ÄÉÆÖÎÁÆЧ¹û£¬£¬ÐèҪѰÕÒ¸üÓÐÓõÄ×ÛºÏÖÎÁÆ·½°¸¡£¡£¡
£¡£

ÓÕµ¼»¯ÁÆÊÇÖ¸ÔÚ·ÅÉäÖÎÁÆǰʹÓõĻ¯ÁÆ£¬£¬¾ßÓл¼Õß˳ӦÐԺ㬣¬Ìá¸ß·ÅÁÆÃô¸ÐÐÔÒÔ¼°½µµÍÔ¶´¦×ªÒÆ·çÏÕµÈÓŵã¡£¡£¡
£¡£Ñо¿ÏÔʾ£¬£¬¶àÎ÷ËûÈü£¨Docetaxel£©¡¢¡¢¡¢Ë³²¬£¨Cisplatin£©ÁªºÏ·úÄòà×ण¨Fluorouracil£©×é³ÉµÄTPFÓÕµ¼»¯ÁÆ£¬£¬ÏÔÖøÌá¸ßϳ¡²¿ÍíÆÚÍ·¾±ÁÛ°©»¼ÕßµÄÉúÑÄ£¬£¬ÊÇÍ·¾±ÁÛ°©Ê×Ñ¡µÄÓÕµ¼»¯ÁÆ·½°¸£¬£¬µ«ÔÚͬÆÚ·Å»¯ÁƵĻù´¡ÉÏ£¬£¬¼ÓÓÃTPFÓÕµ¼»¯ÁÆÄÜ·ñ½øÒ»²½Ìá¸ß¾Ö²¿ÇøÓòÍíÆÚ±ÇÑÊ°©µÄÁÆЧÉÐδÃ÷È·¡£¡£¡
£¡£

Ϊ´Ë£¬£¬ÎÒÃÇÍŶÓǣͷÌìÏÂ10¼Ò3¼×Ò½Ôº£¬£¬Àúʱ8ÄêÅäºÏÍê³ÉÁËÒ»ÏîÇ°Õ°ÐÔ¶àÖÐÐÄIIIÆÚËæ»ú±ÈÕÕÁÙ´²ÊÔÑ飬£¬½«Èë×黼ÕßËæ»ú·ÖÈëTPFÓÕµ¼»¯ÁÆÁªÌõÔ¼ÆÚ·Å»¯ÁÆ×飨ÊÔÑé×飩»òͬÆÚ·Å»¯ÁÆ×飨±ÈÕÕ×飩£¬£¬½ÏÁ¿Á½×éµÄÉúÑÄÂʼ°¶¾¸±·´Ó³¡£¡£¡
£¡£¸ÃÑо¿ÔÚ¹ú¼ÊÉÏÊ×´Î֤ʵÓÕµ¼»¯ÁÆÄܹ»Ìá¸ß±ÇÑÊ°©µÄÁÆЧÇÒÖÎÁƶ¾ÐÔ¿ÉÒÔÄÍÊÜ£¬£¬²¡È˵ÄÉúÑÄÂÊÌá¸ßÁË8%£¬£¬Ö×ÁöתÒƵı¬·¢ÂʽµµÍÁË7%¡£¡£¡
£¡£Ñо¿Ð§¹ûÔÚÈ«ÇòÅÅÃûµÚÒ»µÄÖ×ÁöѧÔÓÖ¾¡¶ÁøÒ¶µ¶?Ö×Áö¡·½ÒÏþ¡£¡£¡
£¡£ÕâÊǽü10ÄêÀ´Î¨Ò»Äܹ»Ìá¸ß¾Ö²¿ÍíÆÚ±ÇÑÊ°©ÉúÑÄÂÊ£¬£¬ïÔÌ­Ö×ÁöÀ©É¢µÄ3ÆÚÁÙ´²ÊÔÑ飬£¬ÓÐÍûÔÚ²»¾ÃµÄδÀ´±»ÃÀ¹úºÍÅ·ÖÞµÄÖ¸ÄÏËù½ÓÄÉ£¬£¬ÔÚÈ«ÌìÏÂÍƹãÓ¦Óᣡ£¡
£¡£¹ú¼ÊÙÉÐÐÖ¥¼Ó¸ç´óѧҽѧÖÐÐÄMichael T Spiotto½ÌÊÚ½ÒÏþͬÆÚ̸ÂÛ£¬£¬ÒÔΪ´ËÂÛÎÄΪȷÁ¢±ÇÑÊ°©×î¼Ñ×ÛºÏÖÎÁÆģʽÌṩÁ˸߼¶±ðµÄѭ֤ҽѧ֤¾Ý£¬£¬Ò²ÎªÓÕµ¼»¯ÁÆÔÚÆäËüÍ·¾±Ö×ÁöÖеÄÓ¦ÓÃÌṩÁËеÄÑо¿Ë¼Ð÷¡£¡£¡
£¡£±ðµÄ£¬£¬Öйú¡¶¿µ½¡±¨¡·Í·°æÍ·ÌõÒÔ¡¶±ÇÑÊ°©ÖÎÁÆÎÒ¹úÔÙ¶ÈÁìÅÜ¡·ÎªÌâ¾ÙÐб¨µÀ²¢½ÒÏþÌØԼ̸ÂÛ£º£º¡¶ÁìÅÜÕ߸üÐèҪȫ·½Î»Ö§³Ö¡·£¬£¬Í¬Ê±¸ÃÏîÑо¿Ð§¹û»ñµÃ¿Æ¼¼ÈÕ±¨¡¢¡¢¡¢ÖйúҽѧÂÛ̳±¨¡¢¡¢¡¢¿µ½¡±¨¡¢¡¢¡¢Ò½Ê¦±¨ºÍ¹ãÖÝÈÕ±¨µÈº£ÄÚÍâÖ÷Á÷ýÌå10Óà´ÎÕýÃ汨µÀ¡£¡£¡
£¡£

Lancet Oncol. 2016;17(11):1509-20. (¿ìËÙ±¨µÀ) (IF 33.9)

ͨ¹ýÒ»Ïî¶àÖÐÐÄIIIÆÚÁÙ´²ÊÔÑé·¢Ã÷£¬£¬ÔÚÖÐÍíÆÚ±ÇÑÊ°©»¼ÕßÖУ¬£¬ÐµÄÈýÒ©ÁªºÏÓÕµ¼»¯ÁÆ·½°¸

£¨¶àÎ÷ËûÈü+˳²¬+·úÄòà×ण©ÄܽøÒ»²½Ìá¸ßÉúÑÄÂÊ¡£¡£¡
£¡£

¼Ç£º£ºÇë½éÉÜһϿÎÌâ×éÆäËûÖ÷ÒªÑо¿Ð§¹û¼°ÆäÁÙ´²ÔËÓüÛÖµ£¿
£¿

Âí£º£º¿Æѧ·¢Ã÷Ò»£º£ºÃ÷È·¸¨Öú»¯ÁƲ»¿É½øÒ»²½¸ÄÉÆÖÐÍíÆÚ±ÇÑÊ°©µÄÉúÑÄ£¬£¬´Ó¶øʹ»¼Õß×èֹ̫¹ýÖÎÁÆ£¬£¬ºÏÀíʹÓÃÒ½ÁÆ×ÊÔ´¡£¡£¡
£¡£·ÅÉäÖÎÁƼò³Æ·ÅÁÆ£¬£¬Êǹú¼Ê¹«ÈϵıÇÑÊ°©Ö÷ÒªÖÎÁÆÒªÁ죬£¬ËüÊÇʹÓüÓËÙÆ÷±¬·¢µÄÉäÏߣ¬£¬´ÓÌåÍâÉäÈ룬£¬É±ÃðÖ×Áö¡£¡£¡
£¡£ÍíÆÚ±ÇÑÊ°©»¼ÕßÒª²»ÒªÔÚ·ÅÁÆ¿¢ÊºóÔÙ´ò»¯ÁÆ£¿
£¿ÕâÊǺã¾ÃÀ§ÈÅÒ½ÉúºÍ²¡È˵ÄÒÉÎÊ¡£¡£¡
£¡£×Ô 1998 Äê×îÏÈ£¬£¬ÃÀ¹úÖ¸ÄÏÍƼöËùÓÐÖÐÍíÆÚ±ÇÑÊ°©»¼Õß½ÓÊܸ¨Öú»¯ÁÆ£¬£¬Ò²¾ÍÊÇ×öÍê·ÅÁƺóÔÙ´òÈý¸öÁƳ̵Ļ¯ÁÆ£¬£¬ÕâÒ»·½°¸³ÉΪ¹ú¼ÊÉÏͨÓõıê×¼¡£¡£¡
£¡£È»¶ø£¬£¬Æ¾Ö¤ÔÚ±ÇÑÊ°©ÕïÁÆÒ»Ïß·ÜÕ½¶þÊ®¶àÄêµÄÂÄÀú£¬£¬·¢Ã÷ʹÓÃÕâÒ»·½°¸£¬£¬²¡ÈËÔâÊÜÐí¶àÍ´¿à£¬£¬Ð§¹ûÈ´²¢²»²ÇÏë¡£¡£¡
£¡£´Ó 2003 Äê×îÏÈ£¬£¬ÎÒÃÇÍŶӿªÕ¹ÁËÒ»Ïî´óÐÍÁÙ´²Ñо¿£¬£¬·¢Ã÷¸¨Öú»¯ÁƲ»¿ÉÌá¸ß±ÇÑÊ°©µÄÁÆЧ¡£¡£¡
£¡£Ïà·´£¬£¬ÔÚ½ÓÊܸ¨Öú»¯ÁƵıÇÑÊ°©²¡ÈËÖУ¬£¬½üÒ»°ë»á±¬·¢ÑÏÖØÍÂÄæµÈ¶¾¸±×÷Óᣡ£¡
£¡£ÕâÒ»Ñо¿Àúʱ¿ìÒª 10 Ä꣬£¬ÓÚ 2012 Äê½ÒÏþÓÚ¹ú¼ÊȨÍþµÄѧÊõÆÚ¿¯¡¶ÁøÒ¶µ¶¡¤Ö×Áö¡·¡£¡£¡
£¡£Æ¾Ö¤ÕâÒ»Ñо¿£¬£¬ÍíÆÚ±ÇÑÊ°©²¡ÈË¿ÉÒÔ×èÖ¹¸¨Öú»¯ÁÆ´øÀ´µÄÍ´¿à£¬£¬½ÚÔ¼ÖÎÁÆÓöÈÒ»Íò¶àÔª£¬£¬ïÔÌ­Èý¸öÔµÄÖÎÁÆʱ¼ä¡£¡£¡
£¡£ÏÖÔÚÃÀ¹úºÍÅ·ÖÞµÄÖ¸ÄÏÒѾ­½ÓÄÉÕâÒ»Ñо¿Ð§¹û£¬£¬¼ÈÄÜʹ²¡ÈË×èÖ¹²»ÐëÒªµÄÖÎÁÆ£¬£¬ÓÖ×èÖ¹ÁËÒ½ÁÆ×ÊÔ´µÄÆÌÕÅ¡£¡£¡
£¡£´ËÑо¿Ð§¹ûͬʱÈëÑ¡2012Äê¡°º£ÄÚҽѧʮ´óÐÂÎÅÊÂÎñ¡± ¼°¡°Öйú¸ßµÈѧУʮ´ó¿Æ¼¼Ï£Íû¡±¡£¡£¡
£¡£

Lancet Oncology. 2012;13(2):163-71. (¿ìËÙ±¨µÀ) (IF 33.9)

Ê×´ÎÃ÷È·¸¨Öú»¯ÁƲ»¿É½øÒ»²½¸ÄÉÆÖÐÍíÆÚ±ÇÑÊ°©µÄÉúÑÄ£¬£¬ÆäÒâÒåÔÚÓÚʹ»¼Õß×èֹ̫¹ýÖÎÁÆ£¬£¬ºÏÀíʹÓÃÒ½ÁÆ×ÊÔ´¡£¡£¡
£¡£

¿Æѧ·¢Ã÷¶þ£º£º·¢Ã÷Ìض¨µÄÒ»×émiRNA±êÇ©Äܹ»·´Ó³×ªÒÆDZÄÜ£¬£¬Ìá¸ßÔ¤ºóÔ¤²âµÄ׼ȷÐÔ£¬£¬Îª¾«×¼ÖÎÁƵÓÚ¨ÁË»ù´¡¡£¡£¡
£¡£Ñо¿Ð§¹ûÓÚ 2012 Äê½ÒÏþÔÚ½ÒÏþ¹ú¼ÊȨÍþµÄѧÊõÆÚ¿¯¡¶ÁøÒ¶µ¶¡¤Ö×Áö¡·ÉÏ£¬£¬Ð¼ÓƹúÁ¢°©Ö¢ÖÐÐÄ»¯ÁÆ¿ÆÖ÷ÈÎHan Chong Toh½ÌÊÚÔÚLancet OncologyͬÆÚÆÀÊöÖÐÖ¸³ö£¬£¬´ËÂÛÎĵÄÑо¿Ð§¹û¿ÉЭÖúÁÙ´²Ò½Éú¸ü׼ȷµØÇø·Ö¸ß·çÏյĻ¼Õߣ¬£¬´Ó¶øÓÐÕë¶ÔÐÔµØÖƶ©ÖÎÁÆ·½°¸£¬£¬Îª±ÇÑÊ°©¡°¸öÌ廯¡±ÖÎÁƵÓÚ¨ÁË»ù´¡¡£¡£¡
£¡£Í¬Ê±£¬£¬¸ÃÂÛÎı»Nature China£¨ÍƹãÖйúÓÅÒì¿ÆѧÑо¿Ð§¹ûµÄרҵÍøÕ¾£©×÷ΪÁÁµãÑо¿ÓèÒÔÍƼö¡£¡£¡
£¡£

Lancet Oncology. 2012;13(6):633-41.(¿ìËÙ±¨µÀ) (IF 33.9) ·¢Ã÷Ìض¨µÄÒ»×émiRNA±êÇ©Äܹ»·´Ó³×ªÒÆDZÄÜ£¬£¬

Ìá¸ßÔ¤ºóÔ¤²âµÄ׼ȷÐÔ£¬£¬Îª¾«×¼ÖÎÁƵÓÚ¨ÁË»ù´¡¡£¡£¡
£¡£

¿Æѧ·¢Ã÷Èý£º£º¹´»æ¡°Î£ÏÕµØÐÎͼ¡±ïÔÌ­·ÅÁƶ¾¸±×÷Óᣡ£¡
£¡£±ÇÑÊÖÜΧÓдóÄÔ¡¢¡¢¡¢ÑÛÇòºÍ¶ú¶äµÈÐí¶àÖ÷ÒªµÄÆ÷¹Ù£¬£¬¹Å°åµÄ·ÅÉäÖÎÁƹæÄ£²¢²»¶ÔÀí£¬£¬µ¼ÖÂÕý³£×éÖ¯ÈÝÒ×Êܵ½ÖêÁ¬£¬£¬ÁÆЧ²î£¬£¬¶¾¸±·´Ó³ºÜ´ó¡£¡£¡
£¡£º£ºÜ³¤Ò»¶Îʱ¼äÄÚ£¬£¬Ö»ÓÐÔ¼ 60%µÄÖÐÍíÆÚ±ÇÑÊ°©²¡ÈËÄÜ´æ»î³¬ 5 Ä꣬£¬ÇÒÖÎÁƺóµÄ·ÅÉäÐÔÄÔ»µËÀµÈºóÒÅÖ¢±¬·¢Âʸߣ¬£¬ÑÏÖØÓ°Ïì×Ų¡È˵ÄÉúÑÄÖÊÁ¿¡£¡£¡
£¡£ÎÒÃÇÍŶÓ̫ͨ¹ýÎöÊýǧÀý²¡È˵Ä×ÊÁÏ£¬£¬»æÖÆÁ˱ÇÑÊ°©À©É¢µÄ¡°Î£ÏÕµØÐÎͼ¡±£¬£¬½«±ÇÑÊ°©À©É¢¹æÄ£·ÖΪ¸ßΣ¡
£¡¢¡¢¡¢ÖÐΣº£ºÍµÍΣÈý¸öÇøÓò£¬£¬Æ¾Ö¤°©Ï¸°ûÀ©É¢Î£ÏնȵIJî±ð£¬£¬µ÷½â·ÅÉäÖÎÁƵĹæÄ£ºÍÇ¿¶È£¬£¬¼È¾«×¼É±Ãð°©Ï¸°û£¬£¬ÓÖ±£»¤ÁËÕý³£×éÖ¯¡£¡£¡
£¡£ÎÒÃÇÁªºÏÃÀ¹ú¡¢¡¢¡¢Ð¼ÓƺÍÖйúÏã¸ÛµÄר¼Ò£¬£¬Í³Ò»»®¶¨Á˱ÇÑÊ°©·ÅÁÆÐèÒª±£»¤´óÄÔ¡¢¡¢¡¢ÑÛ¾¦ºÍ¶ú¶äµÈ 33 ¸öÕý³£Æ÷¹Ù£¬£¬ÖðÒ»½ç¶¨ÁËÕâЩÆ÷¹ÙµÄÇå¾²¹æÄ££¬£¬ÔÚ¹ú¼ÊÉÏÊ×´ÎÌá³öÁ˱ÇÑÊ°©Õý³£Æ÷¹ÙµÄ±£»¤±ê×¼£¬£¬ÔÚ²»ÔöÌíÖ×Áö¸´·¢µÄͬʱ£¬£¬×î´óÏ޶ȵØïÔÌ­¶¾¸±×÷Óᣡ£¡
£¡£Ñо¿½ÒÏþÔÚ·ÅÉäÖÎÁÆÁìÓòÊ×ÇüÒ»Ö¸µÄÖøÃûÆÚ¿¯¡¶·ÅÉäÖÎÁÆÓëÖ×Áöѧ¡·¡£¡£¡
£¡£Ö×Áö·ÀÖÎÖÐÐÄͨ¹ý½ÓÄÉеĵ÷Ç¿·ÅÁÆÊÖÒÕ£¬£¬½«±ÇÑÊ°©²¡È˵ÄÉúÑÄÂÊÌá¸ßÁË10¸ö°Ù·Öµã£¬£¬µÖ´ï80%ÒÔÉÏ£¬£¬·ÅÉäÐÔÄÔ»µËÀµÈÑÏÖغóÒÅÖ¢µÄ±¬·¢ÂʽµµÍÁË24¸ö°Ù·Öµã£¬£¬½µÖÁ44%£¬£¬¼«´óµØÌá¸ßÁ˲¡È˵ÄÉúÑÄÖÊÁ¿¡£¡£¡
£¡£

¼Ç£º£ºÄÜ·ñ̸̸¶Ô±ÇÑÊ°©·ÀÖεÄÌå»áÓëÕ¹Íû?

Âí£º£ºÓÉÓÚ±ÇÑÊ°©²¡±ä²¿Î»Òþ²Ø£¬£¬»¼ÕßÄÑÒÔ²ì¾õ£¬£¬Òò´ËÀ´Ò½Ôº¾ÍÕïµÄ²¡ÈË70%¶¼ÊÇÖÐÍíÆÚ»¼Õߣ¬£¬Æ½¾ùÄêËêÔ¼45Ëê×óÓÒ£¬£¬ÊǼÒÍ¥µÄÖ÷ÒªÀͶ¯Á¦£¬£¬±ÇÑÊ°©ÖÎÁÆÀÖ³ÉÓë·ñ¶Ô²¡È˵ļÒÍ¥ºÍÈËÉúÓÐ×ÅÖ÷ÒªÓ°ÏìºÍÒâÒå¡£¡£¡
£¡£×÷ΪÁÙ´²Ò½Éú£¬£¬ÎÒÃǶԲ¡È˵ÄÄÑ´¦¸üÊÇÉîÓÐÌå»á¡£¡£¡
£¡£Òò´ËÒªÔÚÁÙ´²ÊÂÇéÖз¢Ã÷ÎÊÌ⣬£¬È»ºóÕë¶ÔÁÙ´²ÊÂÇéÖб£´æµÄÎÊÌ⿪չÏà¹ØÑо¿£¬£¬Äܹ»¸üºÃµØ½â¾öÁÙ´²Öб£´æµÄÏÖʵÎÊÌâ¡£¡£¡
£¡£ÓÐÁËÒ»¸öºÃµÄ×ÅÊÖµãºó£¬£¬ÒªÈÏÕæÔúʵ×öÊ£¬£¬Í¬Ê±²»ÒªÃ¤´Ó¡°±ê×¼¡±£¬£¬Òª¸ÒÓÚ¡°ÌôսȨÍþ¡±¡£¡£¡
£¡£Ï£Íû±ÇÑÊ°©ÔÚ¿í´óÙÉÐеÄÅäºÏÆð¾¢ÏÂÄܹ»ÔçÈÕ±»¹¥ÆÆ¡£¡£¡
£¡£

¼Ç£º£º¿ÉÒÔ½éÉÜÒ»ÏÂÍŶÓδÀ´µÄÄ¿µÄÂð£¿
£¿

Âí£º£ºÄܹ»Ê¹±ÇÑÊ°©»¼Õß»ñµÃÔçÆÚÕï¶Ï£¬£¬ÔÚ½øÒ»²½Ìá¸ßÁÆЧµÄ»ù´¡ÉÏ×î´ó³Ì¶ÈµØΪ²¡ÈË¡°¼õ¸º¡±£¬£¬Îª±ÇÑÊ°©µÄ¾«×¼ÖÎÁÆÔçÈÕʵÏÖ¶øÒ»Ö±·ÜÕ½¡£¡£¡
£¡£